Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients.
Kaiyan LiuSydney SternEmily L HeilLinhao LiRula KhairiScott HeywardHongbing WangPublished in: Hepatology communications (2023)
Our findings obtained from in vitro cell-based experiments and patient data analysis provide evidence suggesting combination of DEX and RDV holds the potential to reduce the likelihood of RDV-induced liver injury in hospitalized COVID-19 patients.